Thrombolysis for submassive pulmonary embolus
The use of thrombolytics for the treatment of submassive PE is controversial — the limited documented benefit (e.g. improved hemodynamics, potential for less chronic pulmonary hypertension) must be weighed against the increased risk of life-threatening hemorrhage and the availability of other therapies (e.g. catheter-directed thrombolysis or clot retrieval)